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Quality of life is associated 
with chronic inflammation in 
schizophrenia: a cross-sectional 
study
Faugere M.1,2, Micoulaud-Franchi J.A.3,4, Alessandrini M.2, Richieri R.1,2, Faget-Agius C.1,2,  
Auquier P.2, Lançon C.1,2 & Boyer L.2
Inflammation may play a crucial role in the pathogenesis of schizophrenia. However, the association 
between chronic inflammation and health outcomes in schizophrenia remains unclear, particularly 
for patient-reported outcomes. The aim of this study was to investigate the relationship between 
quality of life (QoL) and chronic inflammation assessed using C -Reactive Protein (CRP) in patients 
with schizophrenia. Two hundred and fifty six patients with schizophrenia were enrolled in this 
study. After adjusting for key socio-demographic and clinical confounding factors, patients with high 
levels of CRP (> 3.0 mg/l) had a lower QoL than patients with normal CRP levels (OR = 0.97, 95% 
CI = 0.94–0.99). An investigation of the dimensions of QoL revealed that psychological well-being, 
physical well-being and sentimental life were the most salient features of QoL associated with CRP. 
Significant associations were found between lower educational level (OR = 4.15, 95% CI = 1.55–11.07), 
higher body mass index (OR = 1.16, 95% CI = 1.06–1.28), higher Fagerström score (OR = 1.22, 95% 
CI = 1.01–1.47) and high levels of CRP. After replications with longitudinal approaches, the association 
between QoL and chronic inflammation may offer interesting interventional prospects to act both on 
inflammation and QoL in patients with schizophrenia.
Schizophrenia occurs in approximately 1% of the population worldwide1. This disorder is a chronic dis-
ease characterised by psychotic symptoms2, cognitive impairment and functional decline3. All of these 
characteristics substantially impact the quality of life (QoL) of patients with schizophrenia4,5. Although 
there is strong evidence that multicomponent treatment involving medication, cognitive behavioural 
therapy, education, and exercise have beneficial effects on symptoms and functioning, most patients still 
have impaired QoL including affective, emotional, and social dimensions6,7. New approaches are there-
fore needed to act efficiently on QoL8.
Recent studies have explored questions about how non-biological factors, including affective, emo-
tional, and social information, may be associated with chronic inflammation. In non-psychiatric pop-
ulations, elevated C - Reactive Protein (CRP) has been reported to be associated with lower QoL level 
amongst the general population9, older individuals10 and in several chronic diseases (e.g., diabetes)11. The 
association between CRP and QoL may therefore offer interesting interventional prospects to act both on 
inflammation and QoL. These findings are of utmost importance in psychiatry, given that inflammatory 
responses and immune reactions may play a crucial role in the pathogenesis of schizophrenia12,13. Various 
studies have reported abnormalities of the immune reactions with the implication of blood lymphocyte 
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abnormalities12, cytokine alterations13, oxidative stress anomalies14 and CRP elevations15 in schizophre-
nia. From a clinical perspective, elevated CRP levels are associated in schizophrenia with some pejorative 
psychiatric features16, high psychotic symptoms17,18 and high cognitive impairment19 . Moreover, elevated 
CRP levels are also associated with metabolic syndrome20 and high cardiovascular disease risk21. All of 
the clinical features that are associated with an elevated CRP level in schizophrenia are known to be 
associated with impaired QoL. Currently, however, no study has specifically investigated the relationship 
between impaired QoL and elevated CRP levels in patients with schizophrenia.
The aim of this study was to investigate the relationship between QoL and chronic inflammation 
assessed using CRP in patients with schizophrenia, in addition to considering key socio-demographic 
and clinical confounding factors.
Methods
Study participants. The study evaluated all prospective patients attending daytime hospital hours 
in our university and psychiatric hospital during a period of 4 years, from June 2010 to September 
2014. The inclusion criteria were as follows: (1) age range 18–85 years old, (2) diagnosis of schizophre-
nia according to the Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM-IV-TR) 
criteria22, (3) antipsychotic medication stable for a minimum of 3 months, and (4) French as a native 
language. The exclusion criteria were as follows: (1) diagnoses other than schizophrenia on Axis I of the 
DSM-IV-TR, except for nicotine dependence, (2) major non-psychiatric disease, (3) mental retardation 
and (4) any identifiable acute, intermittent or chronic infections or being on routine anti-inflammatory 
or immunosuppressive therapy: a clinical examination was performed, based on interrogatory about 
infectious signs and history, physical examination (including the following examination: temperature, 
weight, mouth, lymph nodes, abdomen, skin and cardiopulmonary auscultation) and serology (HIV, 
HBV and HCV). The data collection was approved by the Commission Nationale de l’Informatique et 
des Libertés (CNIL number 1223715). This study was constructed in accordance with the Declaration 
of Helsinki and French good clinical practices23. All of the patients were informed of the study and gave 
written, informed consent after a standardised and structured clinical interview.
Data collection. The following data were collected:
1. Socio-demographic information: gender, age, educational level, professional activity.
2. Clinical characteristics: duration of disorder; body mass index (BMI); smoking status assessed 
by the Fagerström Test for Nicotine Dependence (FTND)24; alcohol consumption assessed by the 
Alcohol Use Disorders Identification Test (AUDIT)25; psychotic symptoms based on the Positive 
and Negative Syndrome Scale (PANSS), which consists of three subscales (positive, negative, and 
general psychopathology)26,27.
3. Drug information: antipsychotic medications (presence of atypical antipsychotic), presence of 
clozapine, presence of olanzapine, and chlorpromazine equivalent dose (in milligrams per day). 
Among atypical antipsychotics, clozapine and olanzapine are of specific interest for our study 
because of their potential link to metabolic syndrome and chronic inflammation28–30.
4. QoL measurement: QoL was assessed using the SQoL 18 questionnaire, which is a self-adminis-
tered, multidimensional instrument developed and validated for the specific assessment of QoL in 
patients with schizophrenia31–34. The SQoL 18 consists of 18 items describing the following eight 
dimensions: Psychological Well-being (PsW), Self-Esteem (SE), Family Relationships (RFa), Rela-
tionships with Friends (RFr), Resilience (RE), Physical Well-being (PhW), Autonomy (AU), and 
Sentimental Life (SL) as well as a global score (the index)33. Dimensions and index scores range 
from 0, indicating the lowest QoL, to 100, the highest QoL.
5. Chronic inflammatory marker: serum levels of CRP were determined using sensitive regular 
immunoassays (ELISA). The results are expressed as milligram per litre. The detection limit was 
0.08 μ g/ml. Patients were classified into 2 groups: normal CRP level (≤ 3.0 mg/l) and High CRP 
(> 3.0 mg/l)21,35,36.
Statistical analysis. The characteristics of the entire group of patients with schizophrenia are 
expressed in proportions or as means and standard deviations. The socio-demographic and clinical char-
acteristics, drug information, and QoL were compared between the two groups (normal CRP level vs. 
High CRP) using Student t test for continuous variables and Chi-square test for categorical variables.
A multivariate logistic regression was then performed to estimate the adjusted Odds Ratio (OR) and 
its corresponding 95% confidence interval (CI) for an association between the SQoL 18 index (inde-
pendent variable) and CRP (dependent variable), with adjustment for confounding factors selected from 
the univariate based on a threshold p-value ≤ 0.20 (age, educational level, duration of disorder, BMI, 
Fagerström test and SQoL 18 index were selected). A set of additional variables was included in the mod-
els because of their clinical and socio-demographic interest (gender, presence of atypical antipsychotics, 
AUDIT, PANSS total score)17,18,29,37,38. This analysis was repeated replacing the SQoL 18 index with each 
dimension of the SQoL 18 to determine the most salient features of QoL associated with CRP.
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All of the tests were two-sided. Statistical significance was defined as p < 0.05. Statistical analysis was 
performed using the SPSS version 18.0 software package (SPSS Inc., Chicago, IL, USA).
Results
Patient characteristics. Two hundred fifty six outpatients with schizophrenia participated in our 
study (Table 1). The mean age of the patients was 35.96 years (± 12.01), and 71.9% of the patients were 
male. The patients showed moderate severity of symptoms, with a total PANSS score corresponding to 
71.09 (± 24.40) and sub-scores of 15.20 (± 6.88), 20.00 (± 7.95) and 35.89 (± 12.09), respectively, for 
positive, negative, and general psychopathology factors. Of the total number of patients, the mean chlor-
promazine equivalent dose was 856.69 (± 791.44) milligrams per day; 88.3% were treated by atypical 
antipsychotics, 24.2% were treated by clozapine, and 15.7% were treated by olanzapine.
Comparison of patients with normal CRP level and High CRP. Among the 256 patients with 
schizophrenia, 100 (39.06%) had a high CRP level. Compared to patients with normal CRP levels, those 
with high CRP levels were significantly older (p = 0.027), with a lower education level (p = 0.021), a longer 
duration of disorder (p = 0.018), a higher BMI (p = 0.000) and a higher Fagerström score (p = 0.041). 
Concerning QoL, patients with high CRP levels reported lower QoL scores for the SQoL 18 index, the 
PhW and the SL dimensions (p = 0.016, p = 0.005 and p = 0.003, respectively). A trend was observed for 
the SE, PsW and RE dimensions (p = 0.067, p = 0.076 and p = 0.073, respectively).
Entire Group (N = 256)
Normal CRP 
level ≤3.0 mg (N = 156)
High CRP >3.0 mg 
(N = 100)
Normal CRP 
level vs. High 
CRP p-value
Mean or % SD Mean or % SD Mean or % SD p
Gender (Male) 184 (71.9%) — 116 (74.4%) — 68 (68.0%) — 0.270a
Age (years) 35.96 12.01 34.62 11.60 38.03 12.38 0.027
Education level (> 12 years) 144 (56.3%) — 97 (62.2%) — 47 (47.5%) — 0.021a
Professional activity (yes) 39 (15.2%) — 24 (16.1%) — 15 (15.3%) — 0.866a
Duration of disorder (years) 13.04 9.72 11.86 9.31 14.82 10.11 0.018
Body mass index 26.63 5.35 25.33 4.93 28.68 5.35 0.000
Presence of atypical antipsychotic 226 (88.3%) — 136 (87.2%) — 90 (90.0%) — 0.494a
Presence of Clozapine 62 (24.2%) — 36 (23.1%) — 26 (26.0%) — 0.594a
Presence of Olanzapine 40 (15.6%) — 27 (17.3%) — 13 (13.0%) — 0.354a
Chlorpromazine equivalent dose 
(mg/day) 856.69 791.44 844.31 899.46 875.76 591.47 0.758
Fagerström test 5.36 2.724 4.98 2.80 5.88 2.55 0.041
AUDITb 6.33 7.76 6.60 8.09 5.99 7.34 0.627
PANSSc Total 71.09 24.40 70.33 25.16 72.27 23.24 0.535
PANSS Positive factor 15.20 6.88 14.82 7.07 15.79 6.56 0.272
PANSS Negative factor 20.00 7.95 19.95 8.14 20.08 7.69 0.898
PANSS General psychopathology 
factor 35.89 12.09 35.56 12.46 36.40 11.54 0.588
SQoL 18d index 54.87 19.14 57.22 19.35 51.27 18.32 0.016
Psychological Well-being 57.60 28.72 60.20 30.03 53.62 26.25 0.076
Self-Esteem 55.88 30.48 58.72 29.97 51.52 30.89 0.067
Family Relationships 62.55 27.58 64.14 26.40 60.10 29.27 0.257
Relationships with Friends 42.83 31.10 43.09 30.54 42.42 32.08 0.868
Resilience 58.93 27.09 61.40 27.99 55.13 25.33 0.073
Physical Well-being 56.82 26.37 60.77 23.20 50.76 29.71 0.005
Autonomy 62.05 28.20 62.66 28.26 61.11 28.23 0.671
Sentimental Life 42.33 29.74 46.79 30.40 35.48 27.47 0.003
Table 1.  Socio-demographic and clinical characteristics of the study sample (n = 256). aχ 2 test for 
qualitative variables bAlcohol Use Disorders Identification Test cPositive And Negative Syndrome Scale 
dSchizophrenia Quality of Life questionnaire 18: Scores range from 0 to 100; higher scores represent higher 
QoL.
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Factors associated with High CRP. In the multivariate analyses reported in Tables  2 and 3, the 
relationship between the SQoL 18 index score and CRP level remained significant after adjusting for 
socio-demographic, clinical and drug characteristics. An educational level ≤ 12 years, a higher BMI and 
a higher Fagerström score remained significantly associated with high CRP level. An investigation of the 
various dimensions of the SQoL 18 revealed that PsW, PhW and SL were the most salient features of 
QoL associated with CRP. A trend was observed for the SE dimension.
Discussion
This study investigated the relationship between QoL and chronic inflammation in patients with schizo-
phrenia. Our findings provide evidence for a moderate association between high CRP levels and low QoL 
levels, including psychological well-being, physical well-being and sentimental life dimensions of QoL. 
Additionally, low educational level, high BMI and high Fagerström score also showed a significant rela-
tionship with high CRP level, whereas the severity of psychotic symptoms was not associated with CRP.
The main finding of our study is the existence of the relationship between QoL and chronic inflamma-
tion in patients with schizophrenia, after adjusting for key socio-demographic and clinical confounding 
factors. These findings support previous studies that reported the association between low QoL levels 
and high CRP levels amongst non-psychiatric populations9–11. However, the cross-sectional design of our 
study precludes any conclusions about the directionality of the association between QoL and inflamma-
tion in schizophrenia.
We hypothesise that QoL through its psychological, physical and social features predicts chronic inflam-
mation in schizophrenia. Several studies reported that psychosocial factors, including poor well-being, 
Factors
Adjusted 
odds ratio 95%CIa p-value
Gender (/Male) 0.50 0.17-1.49 0.216
Age (years) 1.03 0.97-1.09 0.291
Education level (/> 12 
years) 4.15 1.55-11.07 0.005




Duration of disorder 
(years) 1.01 0.94-1.09 0.794
Body mass index 1.16 1.06-1.28 0.002
Fagerström Test 1.22 1.01-1.47 0.043
AUDITb 1.01 0.95-1.07 0.721
PANSSc total 0.99 0.97-1.01 0.392
SQoL 18d index 0.97 0.94-0.99 0.021
Table 2.  Factors associated with high CRP: multivariate analysis. aConfidence Interval bAlcohol Use 






Psychological Well-being 0.98 0.96-0.99 0.020
Self-Esteem 0.99 0.97-1.00 0.082
Family Relationships 1.00 0.98-1.02 0.995
Relationships with Friends 0.99 0.98-1.01 0.329
Resilience 0.99 0.97-1.00 0.110
Physical Well-being 0.97 0.95-0.99 0.005
Autonomy 0.99 0.98-1.01 0.534
Sentimental Life 0.98 0.97-0.99 0.015
Table 3.  SQoL 18 dimensions scores associated with high CRP: multivariate analyses. aSchizophrenia 
Quality of Life questionnaire 18: scores range from 0 to 100; higher scores represent higher QoL. 
bConfidence Interval.
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were predictors of chronic inflammation and poor health39. The influence of psychological well-being 
on CRP may be supported by studies that reported an association between psychological stress and the 
dysregulation of the hypothalamic-pituitary-adrenal axis involved in inflammation40. Physical well-being 
may result from the physical fitness of individuals, which is also involved in inflammatory processes. 
Physically fit individuals demonstrate lower inflammatory responses to mental stress41. Moreover, regular 
exercise has been consistently associated with anti-inflammatory effects, whereas sedentary behaviour is 
now considered an important risk factor for inflammation and many health conditions independent of 
physical activity levels42. Concerning the relationship between sentimental life and CRP, a growing body 
of literature has revealed the biophysiological mechanisms underlying the associations between social 
disconnectedness and chronic inflammation, which play an important role in health and longevity43,44. 
A recent study has also reported that the elevation of CRP could be limited by the marital status of 
individuals45,46. Interestingly, these findings may explain the mechanisms underlying the relationship 
between QoL and relapse in schizophrenia. QoL has been reported to be an independent predictor for 
relapse in schizophrenia, more than the severity of symptoms47. It may be that relapse is triggered by 
mechanisms associated with inflammatory processes associated with QoL changes. Taken together, these 
findings raise the possibility that patients with schizophrenia destined to develop chronic inflammation 
might be identifiable using QoL measures and might potentially benefit from adapted therapeutic strat-
egies to prevent it. QoL could therefore be considered a reliable predictor of chronic inflammation by 
healthcare professionals. From this perspective, clinicians should be encouraged to think about chronic 
inflammation in patients reporting poor QoL.
We also hypothesise that chronic inflammation can cause changes in QoL. In accordance with this 
hypothesis, a recent study suggested that the progression of chronic inflammatory disease may exert a 
significant negative impact on QoL in both emotional and social domains10. This hypothesis may be 
supported by the sickness behavioural model48,49. CRP is a general marker of inflammatory processes and 
is associated with several interleukins (e.g., IL-6) functionally involved in the development of symptoms 
of sickness through direct effects on the central nervous system48. Symptoms of sickness (e.g., fatigue, 
reduced appetite, sleep disorders, altered mood and cognition) are well known to negatively impact QoL 
amongst non-psychiatric populations48. Our results suggest that symptoms of sickness may also be related 
to poor QoL in patients with schizophrenia. Future studies should confirm this hypothesis and then 
explore the beneficial value of various interventions including pharmaceutical and non-pharmaceutical 
strategies on chronic inflammation, the symptoms of sickness and QoL in patients with schizophrenia.
The association between educational level, BMI, smoking and CRP were expected, confirming the 
findings of most previous studies. A low socioeconomic standing including low education level has been 
found to be associated with chronic inflammation39,50,51. Smoking has been associated with many cardi-
ovascular risk factors, including high CRP levels, which remains in former smokers52,53. By producing 
oxidative stress and stimulating hematopoietic cells, smoking activates pro-inflammatory cytokines (e.g., 
IL-6), which in turn stimulate the production of CRP52,54. Lastly, an increase in macrophage infiltration 
in fat tissues has been observed in excess of weight, which promotes the substantial production of inflam-
matory cytokines55. In contrast, the lack of an association between CRP and symptoms is more surpris-
ing. However, previous studies have reported discordant results on this issue17,19. The inconsistencies may 
be because possible confounding factors (e.g., BMI, smoking, alcohol consumption and antipsychotic 
medications) were rarely considered in previous studies56.
Limitations and perspectives. Several limitations should be considered in our study
First, an important methodological problem is the definition of our groups (normal CRP level and 
high CRP). Indeed, there are no generally accepted criteria for relapse. However, we have chosen the 
most consensual definition in the recent scientific literature, recognized as the cut-off point for high 
cardiovascular risk21,35,36.
Second, CRP was the sole marker of inflammation in this study. Although CRP is strongly associated 
with IL-6 activity, we did not directly assess any of the cytokines. Future studies with extensive assess-
ment of inflammatory markers may be required.
Third, we have only collected CRP at one time point, and repeated testing has been recommended 
to confirm elevated plasma levels35 because concentrations can be affected by acute infection. However, 
patients with acute infections were removed and did not alter any of the results.
Last, although our work accounts for a large set of potentially confounding variables, additional fac-
tors might have been interesting to consider. Particularly, cognitive impairment, a core symptom of 
schizophrenia, is associated with metabolic syndrome57,58 and chronic inflammation19. However, as most 
studies revealed nonsignificant relationships between most neurocognitive measures and QoL59,60, our 
findings should not be modified.
Conclusion
Our study suggests that chronic inflammation is moderatly associated with lower QoL levels in patients 
with schizophrenia. After replications with longitudinal approaches, the association between QoL and 
chronic inflammation may offer interesting interventional prospects to act both on inflammation and 
QoL in patients with schizophrenia. Moreover, it would be important to include systematic measures 
of inflammation markers into future clinical trials or intervention studies in schizophrenia (including 
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cognitive or social interventions) in order to get a broader insight on the effect of those interventions 
which may not only concern clinical symptoms and quality of life but also inflammation markers. Such 
intervention studies may also be relevant to examine the dynamics of the relationship between clinical 
symptoms, QoL and inflammation markers.
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